Home versus Office blood pressure MEasurements: Reduction of Unnecessary treatment Study: Rationale and Study design of the HOMERUS Trial

被引:25
作者
Verberk, WJ
Kroon, AA
Kessels, AGH
Dirksen, C
Nelemans, PJ
Lenders, JWM
Thien, TABM
van Montfrans, GA
Smit, AJ
de Leeuw, PW
机构
[1] Univ Hosp Maastricht, Dept Internal Med, NL-6202 AZ Maastricht, Netherlands
[2] Univ Hosp Maastricht, Dept Clin Epidemiol & Med Technol Assessment, NL-6202 AZ Maastricht, Netherlands
[3] Univ Hosp Maastricht, Dept Epidemiol, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
[5] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Div Gen Internal Med, Nijmegen, Netherlands
[6] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1105 AZ Amsterdam, Netherlands
[7] Univ Hosp Groningen, Dept Internal Med, Groningen, Netherlands
关键词
blood pressure; cost-effectiveness; cost-minimization; home monitoring; hypertension; self-measurements; white coat effect;
D O I
10.1080/08037050310022405
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The Home versus Office MEasurements, Reduction of Unnecessary treatment Study (HOMERUS) is a multicentre prospective study, primarily designed to examine in subjects with mild to moderate hypertension whether treatment decisions based on home blood pressure measurements can lead to reduction in the use of antihypertensive drugs and the associated costs, compared to office blood pressure measurements. After inclusion, 360 patients are randomized to two groups. In one group, antihypertensive therapy is based on blood pressure measured in the outpatient clinic: the office pressure (OP) group. In the other group, antihypertensive therapy is based on home blood pressure measurements: the self-pressure (SP) group. All readings, both in OP and in SP, are obtained with the same validated oscillometric device, the Omron 705 CP. Treatment decisions are taken by an independent physician at the coordinating centre, who is unaware whether the patient belongs to the SP or OP group. Following a standardized treatment schedule, blood pressure is targeted at 120-139 mmHg for systolic and 80-89 mmHg for diastolic pressure. Patients are followed for 1 year. At the start and at the end of the study, ambulatory blood pressure measurements are obtained as a reference. Microalbuminuria and echocardiography are assessed to evaluate the possible development of target organ damage. It is expected that, at the end of the trial, patients in both groups will have the same blood pressure, at the expense of more medication in the OP group. Therefore, a cost-minimization analysis will be performed first. If short-term effects appear not to be comparable for OP and SP, a cost-effectiveness analysis will be performed to assess the value of the SP strategy in comparison to standard practice. In addition, medication compliance is recorded within random subgroups of the SP and OP groups by means of Medication Event Monitoring System (MEMS) V TrackCaps.
引用
收藏
页码:326 / 333
页数:8
相关论文
共 36 条
[11]   Self-measured versus ambulatory blood pressure in the diagnosis of hypertension [J].
Hond, ED ;
Celis, H ;
Fagard, R ;
Keary, L ;
Leeman, M ;
O'Brien, E ;
Vandenhoven, G ;
Staessen, JA .
JOURNAL OF HYPERTENSION, 2003, 21 (04) :717-722
[12]   Predictive values of automated blood pressure measurement: what can we learn from the Japanese population - the Ohasama study [J].
Imai, Y ;
Hozawa, A ;
Ohkubo, T ;
Tsuji, I ;
Yamaguchi, J ;
Matsubara, M ;
Michimata, M ;
Hashimoto, J ;
Fujiwara, T ;
Nagai, K ;
Kitaoka, H ;
Satoh, H ;
Hisamichi, S .
BLOOD PRESSURE MONITORING, 2001, 6 (06) :335-339
[13]  
MACMAHON S, 1994, J HYPERTENS, V12, pS5
[14]   BLOOD-PRESSURE AND HEART-RATE VARIABILITIES IN NORMOTENSIVE AND HYPERTENSIVE HUMAN-BEINGS [J].
MANCIA, G ;
FERRARI, A ;
GREGORINI, L ;
PARATI, G ;
POMIDOSSI, G ;
BERTINIERI, G ;
GRASSI, G ;
DIRIENZO, M ;
PEDOTTI, A ;
ZANCHETTI, A .
CIRCULATION RESEARCH, 1983, 53 (01) :96-104
[15]  
Marchiando RJ, 2003, AM FAM PHYSICIAN, V67, P2343
[16]   What is the value of home (self) blood pressure monitoring in patients with hypertensive heart disease? [J].
Mengden, T ;
Schwartzkopff, B ;
Strauer, BE .
AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (07) :813-819
[17]  
O'Brien, 1996, Blood Press Monit, V1, P55
[18]   State of the market for devices for blood pressure measurement [J].
O'Brien, E .
BLOOD PRESSURE MONITORING, 2001, 6 (06) :281-286
[19]   Standardisation of costs - The Dutch manual for costing in economic evaluations [J].
Oostenbrink, JB ;
Koopmanschap, MA ;
Rutten, FFH .
PHARMACOECONOMICS, 2002, 20 (07) :443-454
[20]   Too much of a good thing? A critique of overemphasis on the use of ambulatory blood pressure monitoring in clinical practice [J].
Palatini, P .
JOURNAL OF HYPERTENSION, 2002, 20 (10) :1917-1923